Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02925078 · ClinicalTrials.gov registry record · NA
Influence of Mucosa Tissue Thickness on Marginal Bone Loss of Implants With Smooth Collars
A NA study, sponsored by University of Michigan.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT02925078: Completed NA study, sponsored by University of Michigan.
NCT02925078 is a NA study that has completed, run by University of Michigan. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02925078, a NA study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the amount of implant marginal bone loss radiographically and probing depth in between thin and thick mucosa group that will receive a machined collar implant. Null hypothesis is mucosa thickness does not affect implant marginal bone loss on implant with smooth collar.
Primary Outcome
Radiographic change in remaining bone level (measured in millimeters) between the surgery visit (baseline) and the 12 month follow up visit.
Interventions
- DEVICE Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-11-21 |
| Est. Completion | 2019-12-16 |
| Phase | NA |
What the finished NCT02925078 record still lists
NCT02925078 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT) is the first listed.
NCT02925078 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02925078 about?
NCT02925078 is a clinical study titled "Influence of Mucosa Tissue Thickness on Marginal Bone Loss of Implants With Smooth Collars". The primary objective of this study is to compare the amount of implant marginal bone loss radiographically and probing depth in between thin and thick mucosa group that will receive a machined collar implant. Null hypothesis is mucosa thickness does not affect implant marginal bone loss on implant...
What is the current status of trial NCT02925078?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2016-11-21. Estimated completion is 2019-12-16.
What interventions are being tested in trial NCT02925078?
The interventions under investigation include: Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT) (DEVICE).
Who is sponsoring clinical trial NCT02925078?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02925078's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI